《2009-亚太地区非处方药行业分析与预测 OTC Pharmaceuticals in Asia-Pacific.pdf》由会员分享，可在线阅读，更多相关《2009-亚太地区非处方药行业分析与预测 OTC Pharmaceuticals in Asia-Pacific.pdf（42页珍藏版）》请在三一文库上搜索。
1、 Datamonitor USA 245 Fifth Avenue 4th Floor New York, NY 10016 USA t: +1 212 686 7400 f: +1 212 686 2626 e: Datamonitor Europe 119 Farringdon Road London EC1R 3DA United Kingdom t: +44 20 7551 9000 f: +44 20 7675 7500 e: Datamonitor Middle East and North America Datamonitor PO Box 24893 Dubai, UA
2、E t: +49 69 9754 4517 f: +49 69 9754 4900 e: datamonitormena Datamonitor Asia Pacific Level 46, 2 Park Street Sydney, NSW 2000 Australia t: +61 2 8705 6900 f: +61 2 8705 6901 e: Asia-Pacific - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be p
3、hotocopied Page 1 INDUSTRY PROFILE OTC Pharmaceuticals in Asia-Pacific Reference Code: 0200-0364 Publication Date: July 2010 EXECUTIVE SUMMARY Asia-Pacific - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be photocopied Page 2 EXECUTIVE SUMMARY M
4、arket value The Asia-Pacific OTC pharmaceuticals market grew by 4.6% in 2009 to reach a value of $29,948.5 million. Market value forecast In 2014, the Asia-Pacific OTC pharmaceuticals market is forecast to have a value of $37,136.9 million, an increase of 24% since 2009. Market segmentation I Tradit
5、ional medicines is the largest segment of the OTC pharmaceuticals market in Asia-Pacific, accounting for 33.4% of the markets total value. Market segmentation II Japan accounts for 36.4% of the Asia-Pacific OTC pharmaceuticals market value. Market share Johnson a much less costly business model than
6、 developing branded drugs. In developing countries, OTC drug manufacturers are much more likely to be generic firms and traditional medicine manufacturers. In these countries, regulation of prescription drugs is not always distinguished from OTC drugs. Most countries in the region have regulatory au
7、thorities for drug approval, such as the State Food and Drug Administration in China. There are opportunities for new companies in over-the-counter drugs with the strong growth of the market. There is also strong growth potential in developing markets due to the liberalization of distribution channe
8、ls and increasing awareness of health issues in these regions. In the pharmaceutical industry, product recalls can damage brand image, and issues over the safety of drugs can impact end-user decisions to purchase OTC drugs, lowering switching costs. Even in this market where some products are highly
9、 important to the end user, FIVE FORCES ANALYSIS Asia-Pacific - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be photocopied Page 19 customer preferences can have a strong pull-through on manufacturers. However, it is unusual for an OTC drug to
10、be withdrawn from the market due to safety issues although there have been a few instances. Drugs often become over the counter by switching from a prescription drug which can increase consumer confidence in the product. Overall the threat of new entrants is moderate. FIVE FORCES ANALYSIS Asia-Pacif
11、ic - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be photocopied Page 20 Substitutes Figure 9: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Asia-Pacific, 2009 Source: Datamonitor D A T A M O N I T O R Presc
12、ription drugs offer an obvious substitute to OTC pharmaceuticals, but these are normally suited to treating more serious ailments, and thus largely fail to encroach into the OTC market. Moreover most pharmaceutical companies produce both OTC and prescription drugs, which diminishes any threat from t
13、his particular substitute. Many consumers now use alternative medicines, like homeopathy but often in conjunction with conventional medicine, thereby making them less threatening, and more complementary. Sustained use of alternative medicines instead of scientific preparations is often linked with a
14、dherence to an alternative lifestyle,. Thus, while there is niche demand for such products, the majority of the populace is unlikely to view alternative medicines as a viable alternative to OTC pharmaceuticals. Overall the threat from substitutes is assessed as weak. FIVE FORCES ANALYSIS Asia-Pacifi
15、c - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be photocopied Page 21 Rivalry Figure 10: Drivers of degree of rivalry in the OTC pharmaceuticals market in Asia-Pacific, 2009 Source: Datamonitor D A T A M O N I T O R The OTC pharmaceutical ind
16、ustry is witnessing increasing consolidation of leading and bigger companies and more competition. Most of the leading firms are large multinationals, and their wide geographic spread reduces rivalry. However, these firms have typically high fixed costs, as drug research and development requires con
17、tinued investment. Exit barriers are fairly high as most companies that manufacture OTC drugs are focused on the pharmaceutical market and are similar to one another. However, some personal care companies operate in the OTC drugs market or even in prescription pharmaceuticals meaning that exit barri
18、ers are lowered for these companies. For example, Reckitt Benckiser owns the Nurofen and Strepsils brand after acquiring Boots Healthcare International and is also primarily involved in the production and distribution of household cleaning and personal care products. In this market, manufacturers ca
19、n differentiate by demonstrating a drug that has a greater clinical benefit than another and also through a strong brand image. For example, Ibuprofen is a popular painkiller but Nurofen is the best known brand which has achieved strong sales. Sales growth has been sustained by innovation and extens
20、ions to the product, for example the production of Nurofen fast relief. The growth of Asia-Pacific market mitigates rivalry somewhat. Overall, rivalry with respect to the OTC drugs market is moderate. LEADING COMPANIES Asia-Pacific - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile i
21、s a licensed product and is not to be photocopied Page 22 LEADING COMPANIES Johnson Tylenol acetaminophen products; Sudafed cold, flu and allergy products; Zyrtec allergy products; Motrin IB ibuprofen products; and Pepcid AC Acid Controller from Johnson Topamax (topiramate), approved for adjunctive
22、and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; and Procrit (Epoetinalfa, sold outside the US as Eprex), to stimulate red blood cell production. J Levaquin (levofloxacin) and Floxin (ofloxacin), both in the anti-infective field. Furthermore, the company offer
23、s Concerta (methylphenidate HCl) for the treatment of attention deficit hyperactivity disorder; Aciphex/Pariet, a proton pump inhibitor co-marketed with Eisa; and Duragesic/Fentanyl Transdermal (fentanyl transdermal system, sold outside the US as Durogesic), a treatment for chronic pain that offers
24、a novel delivery system. The medical devices and diagnostics segment offers a wide range of products used principally in the professional fields of physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. The products are distributed to wholesalers, hospitals and retailers. Th
25、e segment offers Cordis circulatory disease management products; DePuys orthopedic joint reconstruction, spinal care and sports medicine products; Ethicons surgical care and womens health products. It also offers Ethicon Endo-Surgerys minimally invasive surgical products; LifeScans blood glucose mon
26、itoring and insulin delivery products; Ortho-Clinical Diagnostics professional diagnostic products and Vistakons disposable contact lenses. The distribution to the health care professional markets is undertaken both directly and through surgical supply and other dealers. The international business o
27、f J oncology; neuroscience and ophthalmics; respiratory; immunology and infectious diseases. The pharmaceuticals division is organized into global business franchises for the marketing of various products. The company also operates a business unit under pharmaceuticals division, Novartis Oncology, w
28、hich globally develops and markets oncology products. The division is made up of approximately 80 affiliated companies which employed 56,310 associates in 2009, and selling products in approximately 140 countries. The product portfolio of the pharmaceuticals division includes more than 50 key market
29、ed products. In addition, the divisions portfolio of development projects includes 145 potential new products, new indications or new formulations for existing products in various stages of clinical development. The vaccines and diagnostics division focuses on the research, development, manufacture
30、and marketing of preventive vaccine treatments and diagnostic tools. The division was formed in 2006 following the acquisition of a stake in Chiron. The division has two activities: Novartis Vaccines and Chiron. Novartis Vacciness major products include influenza, meningococcal, pediatric and travel
31、 vaccines. Chiron develops blood screening tools that protect the blood supply. The vaccines and diagnostics division employed 5,416 associates worldwide in 20 countries in 2009. The product portfolio of its vaccines and diagnostics division includes more than 20 marketed products. In addition, the
32、divisions portfolio of LEADING COMPANIES Asia-Pacific - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be photocopied Page 28 development projects includes more than 15 potential new products in various stages of clinical development. Sandoz, Nov
33、atiss generic pharmaceuticals company, develops, produces and markets drugs along with pharmaceutical and biotechnological active substances. The division focuses on retail generics, anti- infectives and biopharmaceuticals activities. In retail generics, Sandoz develops and manufactures active ingre
34、dients and finished dosage forms of pharmaceuticals no longer covered by patents and supplying active ingredients to third parties. Under anti-infectives, it develops and manufactures off-patent active pharmaceutical ingredients and intermediates for use by retail generics and for sale to third-part
35、y customers. In biopharmaceuticals, it develops and manufactures protein or biotechnology-based products no longer protected by patents (known as biosimilars or follow-on biologics). Sandoz offers about 1,000 compounds in more than 130 countries. The consumer health division operates through three b
36、usiness units: OTC (over-the-counter medicines), animal health and CIBA Vision. The OTC business unit offers OTC self medications. The OTC business of the country encompasses more than 45 countries. The animal health business unit offers veterinary products for farm and companion animals. The CIBA V
37、ision business unit markets contact lenses and lens care products. In 2009, the consumer health division invested $346 million in research and development, which amounted to 6% of the divisions net sales. The Novartis OTC product categories include analgesics, cough, cold, allergy, gastrointestinal,
38、 skin care and smoking-cessation treatments, as well as mineral supplements. The company markets its OTC products under the brand names Sinecod, Triaminic, Rhinomer, Ascriptin, Bufferin, Myoflex, Maalox, and Slow Fe among others. Key Metrics Novartis generated revenues of $44.3 billion in the financ
39、ial year ended December 2009 (FY2009), an increase of 6.8% as compared to previous year. The companys net income totaled $8.4 billion in FY2009, an increase of 2.5% as compared with 2008. The consumer health division accounted for 13.1% of the total revenues generated by the company in FY2009. The c
40、onsumer health division recorded revenues of $5.8 billion in FY2009. Asia, Africa and Australasia accounted for 18.3% of the total revenues in FY2009. Revenues from Asia, Africa and Australasia reached $8.1 billion in 2009, an increase of 13.3% as compared to 2008. LEADING COMPANIES Asia-Pacific - O
41、TC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be photocopied Page 29 Table 9: Novartis AG: key financials ($) $ million 2005 2006 2007 2008 2009 Revenues 32,212.0 36,031.0 38,072.0 41,459.0 44,267.0 Net income (loss) 6,130.0 7,175.0 11,946.0 8,19
42、5.0 8,400.0 Total assets 57,732.0 68,008.0 75,452.0 78,299.0 95,505.0 Total liabilities 24,568.0 26,714.0 26,056.0 27,862.0 38,043.0 Employees 90,924 100,735 98,200 96,717 99,834 Source: company filings D A T A M O N I T O R Table 10: Novartis AG: key financial ratios Ratio 2005 2006 2007 2008 2009
43、Profit margin 19.0% 19.9% 31.4% 19.8% 19.0% Revenue growth 14.0% 11.9% 5.7% 8.9% 6.8% Asset growth 10.0% 17.8% 10.9% 3.8% 22.0% Liabilities growth 16.0% 8.7% (2.5%) 6.9% 36.5% Debt/asset ratio 42.6% 39.3% 34.5% 35.6% 39.8% Return on assets 11.1% 11.4% 16.7% 10.7% 9.7% Revenue per employee $354,274 $
44、357,681 $387,699 $428,663 $443,406 Profit per employee $67,419 $71,226 $121,650 $84,732 $84,140 Source: company filings D A T A M O N I T O R LEADING COMPANIES Asia-Pacific - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be photocopied Page 30 F
45、igure 13: Novartis AG: revenues Flixotide/Flovent and Becotide/Beclovent, inhaled steroids for the treatment of inflammation associated with asthma and COPD (chronic obstructive pulmonary disease); Serevent, a bronchodilator to treat asthma and COPD; Ventolin, to treat bronchospasm and Flixonase/Fio
46、nase and Beconase, for the treatment of perennial and seasonal rhinitis. The company markets the following products in CNS therapy area: Seroxat/Paxil and Paxil CR, for the treatment of major depressive disorder; Wellbutrin, an anti-depressant; Imigran/Imitrex, for the treatment of migraine and clus
47、ter headache; Lamictal, for the treatment of epilepsy and bipolar disorder; and Requip, for Parkinsons disease and restless legs syndrome (RLS). LEADING COMPANIES Asia-Pacific - OTC Pharmaceuticals 0200 - 0364 - 2009 Datamonitor. This profile is a licensed product and is not to be photocopied Page 3
48、2 GSKs major products in the anti-virals area include: Combivir, Ziagen, Trizivir, Epzicom/Kivexa and Lexiva/Telzir for HIV treatment; Zeffix, for the treatment of Hepatitis B; and Valtrex, for episodic genital herpes. GSK offers the following products for metabolic therapy area: Avandia, an insulin
49、-sensitizing agent; Avandamet, an insulin resistance that decreases glucose production; Avandaryl, an insulin resistance and pancreatic insulin production stimulant; and Bonviva/Boniva, for the treatment of osteoporosis. The company markets about 30 vaccines across the globe. Its major vaccines include Infanrix, a vaccine against diphtheria, tetanus and pertussis; Infanrix penta/Pediarix, for protection against hepatitis B and polio; Infanrix hexa, f